Evidence map›Paper›PMID 26630657›Full record

ArticlePLoS pathogens2015

Utilizing CMP-Sialic Acid Analogs to Unravel Neisseria gonorrhoeae Lipooligosaccharide-Mediated Complement Resistance and Design Novel Therapeutics.

Sunita Gulati, Ian C Schoenhofen, Dennis M Whitfield, Andrew D Cox, Jianjun Li, Frank St Michael, Evgeny V Vinogradov, Jacek Stupak, Bo Zheng, Makoto Ohnishi and 9 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 67 citations in OpenAlex.

  1. Trial
  2. Article
  3. Frontiers in microbiology · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. mBio · 2024
    Article
  9. Review
  10. bioRxiv : the preprint server for biology · 2024
    Article
  11. Article
  12. Review
  13. Immune responses toFrontiers in immunology · 2023
    Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 4 countries.

Sunita GulatiDivision of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
Ian C SchoenhofenHuman Health Therapeutics Portfolio, National Research Council of Canada, Ottawa, Ontario, Canada.
Dennis M WhitfieldHuman Health Therapeutics Portfolio, National Research Council of Canada, Ottawa, Ontario, Canada.
Andrew D CoxHuman Health Therapeutics Portfolio, National Research Council of Canada, Ottawa, Ontario, Canada.
Jianjun LiDivision of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
Frank St MichaelHuman Health Therapeutics Portfolio, National Research Council of Canada, Ottawa, Ontario, Canada.
Evgeny V VinogradovHuman Health Therapeutics Portfolio, National Research Council of Canada, Ottawa, Ontario, Canada.
Jacek StupakHuman Health Therapeutics Portfolio, National Research Council of Canada, Ottawa, Ontario, Canada.
Bo ZhengDivision of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
Makoto OhnishiNational Institute of Infectious Diseases, Tokyo, Japan.
Magnus UnemoWHO Collaborating Centre for Gonorrhoea and Other STIs, Department of Laboratory Medicine, Microbiology, Örebro University Hospital, Örebro, Sweden.
Lisa A LewisDivision of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
Rachel E TaylorBiomedical Sciences Graduate Program, Departments of Medicine and Cellular and Molecular Medicine, Glycobiology Research and Training Center, University of California, San Diego, La Jolla, California, United States of America.
Corinna S LandigBiomedical Sciences Graduate Program, Departments of Medicine and Cellular and Molecular Medicine, Glycobiology Research and Training Center, University of California, San Diego, La Jolla, California, United States of America.
Sandra DiazBiomedical Sciences Graduate Program, Departments of Medicine and Cellular and Molecular Medicine, Glycobiology Research and Training Center, University of California, San Diego, La Jolla, California, United States of America.
George W ReedPreventive and Behavioral Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
Ajit VarkiBiomedical Sciences Graduate Program, Departments of Medicine and Cellular and Molecular Medicine, Glycobiology Research and Training Center, University of California, San Diego, La Jolla, California, United States of America.
Peter A RiceDivision of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
Sanjay RamDivision of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
University of Massachusetts Chan Medical School · USNational Research Council Canada · CAUniversity of California, San Diego · USNational Institute of Infectious Diseases · JPÖrebro University Hospital · SE

Funding

Siglec Modulation of Inflammatory ResponsesP01HL107150 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LE, DZUNG T · 2011 to 2017
$18.0M
BIOSYNTHESIS AND REGULATION OF SUBSTITUTED SIALIC ACIDSR01GM032373 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI VARKI, AJIT P · 1985 to 2022
$6.9M
Immunology of Infection with Neisseria gonorrhoeaeR37AI032725 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RICE, PETER A. · 2004 to 2013
$6.1M
Immune defenses against Neisseria gonorrhoeaeR01AI114790 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RAM, SANJAY, RICE, PETER A. · 2015 to 2019
$3.1M
Vaccines and Immunotherapeutics against gonorrhea in the contex of Chlamydia coU01AI118161 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RAM, SANJAY · 2014 to 2017
$2.0M
IMMUNOLOGY OF INFECTION WITH NEISSERIA GONORRHOEAER01AI032725 · NIAID · BOSTON MEDICAL CENTER · PI RICE, PETER A. · 1993 to 2003
$1.8M
Lipooligosaccharide mimitope vaccines against Neisseria gonorrhoeaeR01AI114710 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI GULATI, SUNITA, RICE, PETER A. · 2015 to 2018
$1.8M
Sialic acid analogs as novel immunotherapeutics against multidrug-resistant gonorrheaR33AI119327 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI GULATI, SUNITA, RAM, SANJAY · 2017 to 2019
$1.4M
Immunology of Infection with Neisseria gonorrhoeaeR56AI032725 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RAM, SANJAY, RICE, PETER A. · 2014 to 2014
$583k
Novel immunotherapeutics against multi-drug resistant Neisseria gonorrhoeaeR21AI111728 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RAM, SANJAY, SHAUGHNESSY, JUTAMAS · 2014 to 2015
$460k
Sialic acid analogs as novel immunotherapeutics against multidrug-resistant gonorrheaR21AI119327 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI GULATI, SUNITA, RAM, SANJAY · 2015 to 2016
$456k
NHLBI NIH HHS P01 HL107150NHLBI NIH HHS P01HL107150NIAID NIH HHS AI032725NIAID NIH HHS AI111728NIAID NIH HHS AI114710NIAID NIH HHS AI114790NIAID NIH HHS AI118161NIAID NIH HHS AI119327NIAID NIH HHS R01 AI032725NIAID NIH HHS R01 AI114710NIAID NIH HHS R01 AI114790NIAID NIH HHS R21 AI111728NIAID NIH HHS R21 AI119327NIAID NIH HHS R33 AI119327NIAID NIH HHS R37 AI032725NIAID NIH HHS R56 AI032725NIAID NIH HHS U01 AI118161NIGMS NIH HHS R01 GM032373NIGMS NIH HHS R01GM32373
6 · The paper itself

Abstract

Neisseria gonorrhoeae deploys a novel immune evasion strategy wherein the lacto-N-neotetraose (LNnT) structure of lipooligosaccharide (LOS) is capped by the bacterial sialyltransferase, using host cytidine-5'-monophosphate (CMP)-activated forms of the nine-carbon nonulosonate (NulO) sugar N-acetyl-neuraminic acid (Neu5Ac), a sialic acid (Sia) abundant in humans. This allows evasion of complement-mediated killing by recruiting factor H (FH), an inhibitor of the alternative complement pathway, and by limiting classical pathway activation ("serum-resistance"). We utilized CMP salts of six additional natural or synthetic NulOs, Neu5Gc, Neu5Gc8Me, Neu5Ac9Ac, Neu5Ac9Az, legionaminic acid (Leg5Ac7Ac) and pseudaminic acid (Pse5Ac7Ac), to define structural requirements of Sia-mediated serum-resistance. While all NulOs except Pse5Ac7Ac were incorporated into the LNnT-LOS, only Neu5Gc incorporation yielded high-level serum-resistance and FH binding that was comparable to Neu5Ac, whereas Neu5Ac9Az and Leg5Ac7Ac incorporation left bacteria fully serum-sensitive and did not enhance FH binding. Neu5Ac9Ac and Neu5Gc8Me rendered bacteria resistant only to low serum concentrations. While serum-resistance mediated by Neu5Ac was associated with classical pathway inhibition (decreased IgG binding and C4 deposition), Leg5Ac7Ac and Neu5Ac9Az incorporation did not inhibit the classical pathway. Remarkably, CMP-Neu5Ac9Az and CMP-Leg5Ac7Ac each prevented serum-resistance despite a 100-fold molar excess of CMP-Neu5Ac in growth media. The concomitant presence of Leg5Ac7Ac and Neu5Ac on LOS resulted in uninhibited classical pathway activation. Surprisingly, despite near-maximal FH binding in this instance, the alternative pathway was not regulated and factor Bb remained associated with bacteria. Intravaginal administration of CMP-Leg5Ac7Ac to BALB/c mice infected with gonorrhea (including a multidrug-resistant isolate) reduced clearance times and infection burden. Bacteria recovered from CMP-Leg5Ac7Ac-treated mice were sensitive to human complement ex vivo, simulating in vitro findings. These data reveal critical roles for the Sia exocyclic side-chain in gonococcal serum-resistance. Such CMP-NulO analogs may provide a novel therapeutic strategy against the global threat of multidrug-resistant gonorrhea.

Indexed as

AnimalsBlotting, WesternComplement System ProteinsCytidine MonophosphateCytidine Monophosphate N-Acetylneuraminic AcidDrug Resistance, MicrobialDrug Resistance, MultipleEnzyme-Linked Immunosorbent AssayFemaleFlow CytometryGonorrheaHumansLipopolysaccharidesMass SpectrometryMiceMice, Inbred BALB CComplement System Proteinscytidine-5'-monophosphosialic acidCytidine MonophosphateCytidine Monophosphate N-Acetylneuraminic Acidlipid-linked oligosaccharidesLipopolysaccharidesSialic Acids

Identifiers

PMID26630657
PMCPMC4668040
OpenAlexW2186297315

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.